Dublin, May 08, 2026 (GLOBE NEWSWIRE) — The “Oncology Companion Diagnostic Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2026-2035” has been added to ResearchAndMarkets.com’s offering.
The global oncology companion diagnostic market is experiencing substantial growth, driven by the increasing integration of precision medicine in cancer treatment. Valued at USD 5.68 billion in 2025, it is anticipated to reach USD 12.84 billion by 2035, achieving a CAGR of 8.50% from 2026 to 2035. This expansion underscores the critical role of diagnostics in tailoring individualized therapies based on molecular and biomarker characteristics.
A significant factor fueling this market growth is the adoption of streamlined regulatory frameworks that expedite the deployment of new diagnostic technologies in clinical settings. Concurrently, the rising use of liquid biopsy is expanding the capabilities of oncology companion diagnostics, enabling minimally invasive biomarker assessment and enhancing cancer management efficiency.
Noteworthy Market Developments
The oncology companion diagnostic market is marked by a competitive landscape featuring major diagnostic players alongside innovative genomic companies. Roche Diagnostics, through its Ventana platform and Foundation Medicine, has established a strong ecosystem encompassing tissue-based immunohistochemistry and comprehensive genomic profiling. This integration bolsters its influence across various segments of oncology testing.
Agilent Technologies also maintains a significant presence, particularly within the PharmDx category, collaborating with pharmaceutical companies to co-develop diagnostics that complement immunotherapy products. These partnerships highlight the strategic importance of companion diagnostics in oncology pipelines by linking therapeutic development and diagnostic commercialization.
Core Growth Drivers
The transition of hospitals and cancer centers towards in-house kitted next-generation sequencing solutions is a key growth driver. This change reduces turnaround time, enhances operational control, and facilitates faster treatment decisions, allowing institutions to deliver results in days rather than weeks. For oncology settings, timely therapy is crucial for impacting outcomes positively.
Emerging Opportunity Trends
Artificial Intelligence is emerging as a significant force in the market, particularly in pathology. AI-driven tools are improving accuracy, consistency, and reproducibility in biomarker assessment, enhancing the reliability of diagnostics and instilling greater confidence in therapeutic decisions.
Barriers to Optimization
The market faces regulatory challenges due to strict, fragmented, and region-specific approval requirements. Differences in standards and timelines between agencies like the FDA and EMA create barriers that extend review periods and inflate costs, hindering the global rollout of new technologies.
Detailed Market Segmentation
- By Product & Services
- By Technology
- Polymerase Chain Reaction (PCR)
- Next-generation Sequencing (NGS)
- Immunohistochemistry (IHC)
- In Situ Hybridization (ISH)/Fluorescence In Situ Hybridization (FISH)
- Other Technologies
- By Disease Type
- Breast Cancer
- Non-small Cell Lung Cancer
- Colorectal Cancer
- Leukemia
- Melanoma
- Prostate Cancer
- Others
- By End-use
- Hospital
- Pathology/Diagnostic Laboratory
- Academic Medical Center
- By Region
- North America
- The US
- Canada
- Mexico
- Europe
- Western Europe
- The UK
- Germany
- France
- Italy
- Spain
- Rest of Western Europe
- Eastern Europe
- Poland
- Russia
- Rest of Eastern Europe
- Asia Pacific
- China
- India
- Japan
- Australia and New Zealand
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- South Africa
- UAE
- Rest of MEA
- South America
- Argentina
- Brazil
- Rest of South America
Geographical Breakdown
Asia Pacific is positioning itself as a vital growth engine with projected expansion rates from 13.3% to 13.55% through 2030. Driven by a vast cancer population and governmental initiatives like China’s Healthy China 2030, the region is advancing domestic next-generation sequencing and AI diagnostic platforms, supporting its dynamic growth.
Leading Market Participants
- Abbott Laboratories
- Agilent Technologies
- Bio-Rad Laboratories
- Biocartis
- Exact Sciences
- Genedrive
- Genomic Health
- Guardant Health
- Illumina
- Invivoscribe
- Myriad Genetics
- QIAGEN
- Roche Diagnostics
- Sysmex Corporation
- Thermo Fisher Scientific
- Other Prominent Players
Key Attributes
| Report Attribute | Details |
| No. of Pages | 240 |
| Forecast Period | 2025-2035 |
| Estimated Market Value (USD) in 2025 | $5.68 Billion |
| Forecasted Market Value (USD) by 2035 | $12.84 Billion |
| Compound Annual Growth Rate | 8.5% |
| Regions Covered | Global |
For more information about this report visit https://www.researchandmarkets.com/r/xlfihh
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Oncology Companion Diagnostic Market
